Download PDF
J Pediatr Genet 2021; 10(04): 300-304
DOI: 10.1055/s-0040-1716707
Original Article

Diagnosis is in the Eye of the Beholder: Barriers to Early Diagnosis of Mucopolysaccharidosis in Children in India

Meenu Grewal
1   Department of Pediatrics, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Parel, Mumbai, Maharashtra, India
,
Mamta Muranjan 
1   Department of Pediatrics, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Parel, Mumbai, Maharashtra, India
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

The present study examined referral pattern and diagnostic practices for mucopolysaccharidosis (MPS) in India in 40 patients with a confirmed diagnosis. Time lag between age of onset of symptoms and consultation with primary physician ranged from 0 to 84 months, between consultation with primary physician and visit to genetic clinic of 0 to 128 months, from visit to genetic clinic and diagnosis of 1 to 111 months, and that between onset of symptoms and diagnosis 1 to 154 months. Major causes for delayed diagnosis were symptoms overlooked by physician (54%), late consultation by care giver (48.6%), late onset of symptoms (43.2%), and resource crunch (32.4%). Diagnosis at referral other than MPS was noted in 45%. Thus, diagnostic delay for MPS is common due to health seeking practices of parents, as well as physicians' clinical practices. Overcoming these barriers would necessitate strengthening awareness and educational activities for physicians and lay public.

Keywords

lysosomal storage disorders - glycosaminoglycans - inborn errors of metabolism

Ethical Approval

This study was reviewed and approved by the Institution's ethics committee.


Authors' Contributions

M.M. conceptualized the study, designed the protocol, supervised data collection and analysis, and wrote the manuscript. M.G. collected and analyzed the data.




Publication History

Received: 31 May 2020

Accepted: 07 August 2020

Article published online:
18 September 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 (Suppl. 05) v49-v59
    CrossrefPubMedGoogle Scholar
  • 2 Sheth J, Mistri M, Sheth F. et al. Burden of lysosomal storage disorders in India: experience of 387 affected children from a single diagnostic facility. JIMD Rep 2014; 12: 51-63
    CrossrefPubMedGoogle Scholar
  • 3 Verma PK, Ranganath P, Dalal AB, Phadke SR. Spectrum of lysosomal storage disorders at a medical genetics center in northern India. Indian Pediatr 2012; 49 (10) 799-804
    CrossrefPubMedGoogle Scholar
  • 4 Kadali S, Kolusu A, Gummadi MR, Undamatla J. The relative frequency of lysosomal storage disorders: a medical genetics referral laboratory's experience from India. J Child Neurol 2014; 29 (10) 1377-1382
    CrossrefPubMedGoogle Scholar
  • 5 Beck M, Arn P, Giugliani R. et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med 2014; 16 (10) 759-765
    CrossrefPubMedGoogle Scholar
  • 6 Bruni S, Lavery C, Broomfield A. The diagnostic journey of patients with mucopolysaccharidosis I: a real-world survey of patient and physician experiences. Mol Genet Metab Rep 2016; 8: 67-73
    CrossrefPubMedGoogle Scholar
  • 7 Giugliani R. Mucopolysacccharidoses: from understanding to treatment, a century of discoveries. Genet Mol Biol 2012; 35 (04) 924-931
    CrossrefPubMedGoogle Scholar
  • 8 Bhattacharya K, Balasubramaniam S, Choy YS. et al. Overcoming the barriers to diagnosis of Morquio A syndrome. Orphanet J Rare Dis 2014; 9: 192
    CrossrefPubMedGoogle Scholar
  • 9 Colmenares-Bonilla D, Esquitin-Garduño N. Diagnosis of Morquio-A patients in Mexico: how far are we from prompt diagnosis?. Intractable Rare Dis Res 2017; 6 (02) 119-123
    CrossrefPubMedGoogle Scholar
  • 10 Kuiper GA, Meijer OLM, Langereis EJ, Wijburg FA. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications. Orphanet J Rare Dis 2018; 13 (01) 2
    CrossrefPubMedGoogle Scholar
  • 11 Kiely BT, Kohler JL, Coletti HY, Poe MD, Escolar ML. Early disease progression of Hurler syndrome. Orphanet J Rare Dis 2017; 12 (01) 32
    CrossrefPubMedGoogle Scholar
  • 12 Wood TC, Harvey K, Beck M. et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis 2013; 36 (02) 293-307
    CrossrefPubMedGoogle Scholar
  • 13 Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr 2013; 102 (05) 462-470
    CrossrefPubMedGoogle Scholar
  • 14 Chakraborty PP, Biswas SN, Ray S, Dey SK. Mucopolysaccharidosis type I disguised as rickets. BMJ Case Rep 2016; 2016: x
    PubMedGoogle Scholar
  • 15 National Health Systems Resource Centre. Household Health Expenditures in India (2013–14). New Delhi, India: Ministry of Health and Family Welfare, Government of India; 2016
    Google Scholar